Latest News

(UroToday.com) While vascular endothelial growth factor (VEGF)-targeted therapy was the standard of care for more than a decade, there have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination […]

(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition to the forefront, subsequent studies have examined combinations of immune checkpoint inhibitors […]

(UroToday.com) One of the fastest moving disease spaces in prostate cancer in metastatic castration sensitive prostate cancer. While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options that have been shown to improve overall survival, including docetaxel and novel hormonal therapies including abiraterone acetate, enzalutamide, and […]

(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis, recently, theranostic treatment with the PSMA-targeting radioligand therapy (TRT) has demonstrated promising activity among pre-treated individuals with […]

(UroToday.com) Surgical excision is the standard of care for patients with non-metastatic renal cell carcinoma (RCC). However, rates of recurrence and progression are not inconsequential and have formed the basis of interest in adjuvant therapy. However, numerous adjuvant VEGF-R targeted tyrosine kinase inhibitor therapy has not been widely adopted as a result of an overall evidentiary […]

Charles Ryan: Hello from ASCO 2021, the virtual meeting. I’m Chuck Ryan from the University of Minnesota, and I’m with Mark Fleming, a longtime friend and medical director of the GU program in US Oncology and a medical oncologist at Virginia Oncology Associates. Welcome, Mark. Good to talk to you again. Mark T. Fleming: Always a […]

(UroToday.com) As part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting’s session entitled “Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?” Dr. Elisabeth Heath discussed differences in prostate cancer patterns and response to treatment, beyond racial differences.

(UroToday.com) Advanced germ cell tumors (GCT) are one of the true success stories of modern oncology in which we can reasonably consider a cure for patients with advanced disease. However, patients may experience late relapse, defined as relapsed disease > 2 years from initial treatment. Such late relapse remains a challenge both in terms of identification […]

(UroToday.com) In the first interim analysis of the randomized, multicenter, open-label, phase 3 KEYNOTE-426 study, treatment with pembrolizumab + axitinib significantly improved OS, PFS, and ORR versus sunitinib monotherapy in treatment-naive advanced clear cell RCC.1 Extended follow-up (median, 30.6 months) continued to demonstrate the superior efficacy of pembrolizumab + axitinib versus sunitinib monotherapy in this patient […]

(UroToday.com) Lenvatinib + pembrolizumab improved PFS, OS, and objective response rate versus sunitinib in the first-line treatment of patients with advanced RCC, while lenvatinib + everolimus improved PFS and objective response rate versus sunitinib.1 The safety profiles of both combinations were consistent with each drug’s known profile and generally manageable, as needed, through dose modifications. At […]